RELATIVE POTENCIES OF PROPOFOL AND METHOHEXITONE INFUSIONS Sir,-We were interested to read the recent paper by Schwilden and colleagues on closed-loop feedback control of propofol anaesthesia using quantitative EEG analysis and comparing this with methohexitone [1] . It is gratifying to find that the required rates of infusion for the two agents, as delivered by closed-loop EEG computer control to volunteers, were similar to our findings in the clinical setting [2] . We used intermittent bolus administration of propofol and methohexitone to provide light general anaesthesia for surgery under regional block, and found a mean administration rate of 7.8 mg kg" 1 h" 1 for propofol and 5.4 mg kg" 1 h" 1 for methohexitone, giving a relative potency of 0.68. Schwilden's volunteers required propofol 1452 mg over 2 h (approximately 10 mg kg" 1 h" 1 for a 70-kg subject) and they demonstrated a relative potency of propofol to methohexitone of 0.72.
In their discussion, however, referring to our paper they state that we gave no data on recovery times. However, we did state that "a particular objective of this study was to assess recovery. Because no other drugs were required this facilitated direct comparison of propofol with methohexitone". We examined both early indices of recovery (eye-opening and repeating date of birth), as did Schwilden, and we included more detailed psychometric assessment involving choice reaction time and critical flicker fusion threshold. Unlike Schwilden, we found no significant differences in recovery times (approximately 9 min for both agents) or in psychometric recovery, attributing this to the intermittent bolus method of administration where we were allowing the effects of one bolus to wear off before giving the next. In a subsequent study using continuous infusions of propofol or methohexitone we found a mean rate of 10.8 mg kg" 1 h" 1 for propofol and 7.8 mg kg" 1 h" 1 for methohexitone was required to provide general anaesthesia without an accompanying regional block-results again very similar to Schwilden's with a relative potency of 0.72. In this study significant differences were seen in respect of recovery times-19 and 25 min from stopping infusion to opening eyes, and 21 and 31 min to repeating date of birth for propofol and methohexitone, respectively.
N. MACKENZIE I. S. GRANT
Dundee
Sir,-Thank you very much for giving me the opportunity to reply to the correspondence from Drs Mackenzie and Grant. Unfortunately, in the final proofs I overlooked the mistyping or error of the language revision. My original manuscript stated in the discussion ' This study gave, however, no evidence for different recovery times for propofol and methohexitone'.
In the printed article, this sentence was modified, omitting the word 'different'.
I regret that I overlooked this omission in the final proofs. I am grateful to Drs Mackenzie and Grant for drawing attention to this error.
H. SCHWILDEN
Bonn ATRACURIUM AND DOUBLE BURST STIMULATION Sir,-We read with interest the article by Engbaek and colleagues [1] on the use of Double Burst Stimulation (DBS) for the assessment of pancuronium-induced neuromuscular block. Our preliminary observations using DBS to assess spontaneous recovery of neuromuscular function following administration of atracurium have been less encouraging.
After opioid premedication, anaesthesia was induced in eight ASA I, adult patients with i.v. thiopentone 5mgkg~'. Nitrous oxide and 0.8% enflurane in oxygen were used to maintain anaesthesia, and neuromuscular block was achieved with a bolus dose of atracurium 0.5 mg kg"'. The lungs were ventilated to maintain PE' COI at 4.5-5.5 kPa. Before administration of atracurium the ulnar nerve at one wrist was stimulated and baseline compound electromyographic potentials from the thenar eminence were recorded using a Datex Relaxograph [2] . The opposite ulnar nerve was stimulated supramaximally using DBS at 5-min intervals. The pattern of stimulation was identical to that used by Engbaek and colleagues [1] , comprising two bursts of three stimuli; the response was evaluated manually at the thenar eminence.
Absence of DBS fade with atracurium was noted first when the mean of the TOF ratio was 29 % (95 % confidence limits 20-37%). This contrasts with the findings of Engbaek and colleagues [1] who demonstrated DBS fade in all patients following pancuronium at this TOF ratio. This apparent discrepancy may result from differences in presynaptic effect between the two agents [3] ; fade during rapid stimulation probably results from prejunctional receptor binding impairing transmitter release [4] . It is therefore unlikely that all neuromuscular blocking agents have similar DBS characteristics.
N. BRAUDE S. GHOSH London
THE OHMEDA OAV 7710 VENTILATOR Sir,-Ohmeda have recently introduced into clinical practice a microprocessor-controlled, electro-pneumatically driven patient ventilator, the OAV 7710.
This ventilator was designed to operate in either a rebreathing (circle) or non-rebreathing mode, the choice being dictated by the selection of the appropriate patient circuit cassette. In the Primary controlled mode the respiratory variables, expired tidal/minute volumes and rate are monitored by a flow transducer which may be placed at any suitable point in the expiratory circuit. The manufacturer recommends that the respirometer unit is placed at the patient end of the breathing circuit. This necessitates the inconvenience of a cable passing from the transducer to the ventilator, and places the transducer in a vulnerable position. Therefore, in clinical practice, the majority of users have placed the transducer unit as shown in the photograph ( fig. 1) . In this position, used in conjunction with an Ohmeda Boyle Mk III absorber (which FIG. 1. Unusual placement of transducer in relation to ventilator.
